Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It is involved in pharmaceutical B2B e-commerce, production, wholesale, and retail businesses, as well as provides logistics services. It offers Western medicine, Chinese patent medicine, Chinese herbal medicine slices and Chinese medicinal materials, food and health f… Read more
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) - Net Assets
Latest net assets as of June 2025: CN¥819.11 Million CNY
Based on the latest financial reports, Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) has net assets worth CN¥819.11 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.75 Billion) and total liabilities (CN¥930.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥819.11 Million |
| % of Total Assets | 46.83% |
| Annual Growth Rate | 11.79% |
| 5-Year Change | 61.97% |
| 10-Year Change | N/A |
| Growth Volatility | 18.64 |
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (2019–2024)
The table below shows the annual net assets of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥850.69 Million | -0.62% |
| 2023-12-31 | CN¥856.04 Million | +4.40% |
| 2022-12-31 | CN¥819.98 Million | +4.07% |
| 2021-12-31 | CN¥787.94 Million | +50.02% |
| 2020-12-31 | CN¥525.23 Million | +7.83% |
| 2019-12-31 | CN¥487.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 57.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥237.60 Million | 27.97% |
| Other Components | CN¥611.93 Million | 72.03% |
| Total Equity | CN¥849.54 Million | 100.00% |
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAMCO Inc
F:SMU
|
$170.96 Million |
|
Guangdong Liantai Environmental Protection Co Ltd
SHG:603797
|
$171.03 Million |
|
BEGBIES TRAYNOR LS -05
F:BTA
|
$171.04 Million |
|
Ningbo Homelink Eco-iTech Co. Ltd.
SHE:301193
|
$171.08 Million |
|
Hy-Lok Corporation
KQ:013030
|
$170.89 Million |
|
Astral Foods Limited
PINK:ALFDF
|
$170.88 Million |
|
JMT Network Services Public Company Limited
BK:JMT
|
$170.83 Million |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
$170.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 854,220,425 to 849,536,749, a change of -4,683,676 (-0.5%).
- Net income of 16,358,248 contributed positively to equity growth.
- Dividend payments of 30,250,596 reduced retained earnings.
- Other factors increased equity by 9,208,672.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥16.36 Million | +1.93% |
| Dividends Paid | CN¥30.25 Million | -3.56% |
| Other Changes | CN¥9.21 Million | +1.08% |
| Total Change | CN¥- | -0.55% |
Book Value vs Market Value Analysis
This analysis compares Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.67x to 3.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥6.63 | CN¥31.00 | x |
| 2020-12-31 | CN¥7.22 | CN¥31.00 | x |
| 2021-12-31 | CN¥8.09 | CN¥31.00 | x |
| 2022-12-31 | CN¥8.51 | CN¥31.00 | x |
| 2023-12-31 | CN¥8.93 | CN¥31.00 | x |
| 2024-12-31 | CN¥8.88 | CN¥31.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.37%
- • Asset Turnover: 2.55x
- • Equity Multiplier: 2.02x
- Recent ROE (1.93%) is below the historical average (6.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 13.59% | 2.82% | 3.08x | 1.56x | CN¥17.09 Million |
| 2020 | 10.43% | 1.94% | 3.30x | 1.63x | CN¥2.22 Million |
| 2021 | 0.83% | 0.19% | 2.86x | 1.53x | CN¥-70.95 Million |
| 2022 | 5.16% | 1.06% | 2.49x | 1.96x | CN¥-39.38 Million |
| 2023 | 6.97% | 1.34% | 2.63x | 1.97x | CN¥-25.89 Million |
| 2024 | 1.93% | 0.37% | 2.55x | 2.02x | CN¥-68.60 Million |
Industry Comparison
This section compares Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,184,328,217
- Average return on equity (ROE) among peers: 9.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | CN¥819.11 Million | 13.59% | 1.14x | $170.91 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Yunnan Hongxiang Yixintang (002727) | $497.43 Million | 20.70% | 1.22x | $545.21 Million |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $450.11 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.78 Billion | 1.93% | 1.96x | $174.48 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |